Samarth Kulkarni - 13 Oct 2023 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Chief Executive Officer, Director
Signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
Issuer symbol
CRSP
Transactions as of
13 Oct 2023
Net transactions value
$0
Form type
4
Filing time
17 Oct 2023, 17:51:04 UTC
Previous filing
23 Jun 2023
Next filing
18 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Stock Option (Right to Buy) Award $0 +52,500 $0.000000 52,500 13 Oct 2023 Common Shares 52,500 $44.31 Direct F1
transaction CRSP Restricted Stock Unit Award $0 +25,000 $0.000000 25,000 13 Oct 2023 Common Shares 25,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on October 13, 2023 with respect to 52,500 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 13, 2023.
F2 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F3 This restricted stock unit award was granted on October 13, 2023 with respect to 25,000 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.